Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled dose-ranging study of LNK01003 in active ulcerative colitis
CTR20221745Phase 2Completed
- Sponsor
- Lynk Pharmaceuticals
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LNK01003 in autoimmune colitis, sponsored by Lynk Pharmaceuticals. Started Nov 2022; status: completed.
02
Drugs
LNK01003
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20221745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221745.